2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-11044
    PF-03654746 Tosylate 1039399-17-1 ≥99.0%
    PF-03654746 Tosylate is a potent, selective and brain-penetrant histamine H3 receptor antagonist. PF-03654746 Tosylate reduces allergen-induced nasal symptoms. PF-03654746 Tosylate has potential for treatment of human cognitive disorders, improves cognitive efficacy and disease-modifying effects in Alzheimer's disease (AD).
    PF-03654746 Tosylate
  • HY-12308
    TCS 2314 317353-73-4 ≥99.0%
    TCS 2314 (compound 3) is orally active and selective very late antigen-4 (VLA-4, α4β1, CD49d/CD29) antagonist with an IC50 of 4.4 nM.
    TCS 2314
  • HY-12633
    GS-6620 1350735-70-4 98.93%
    GS-6620 is potent and selective HCV inhibitor. GS-6620 inhibits HCV replication in genotype 1-6 subgenomic replicons and genotype 2a infectious virus, with EC50 values of 0.048-0.68 μM. GS-6620 can be used for the researches of infection and inflammation, such as Hepatitis C Virus (HCV).
    GS-6620
  • HY-12791
    hPGDS-IN-1 1234708-04-3 99.92%
    hPGDS-IN-1 (Compound 2) is an hPGDS inhibitor with an IC50 of 12 nM (as measured by fluorescence polarization assay or EIA). hPGDS-IN-1 can be used in the research of allergic rhinitis and spinal cord neurons.
    hPGDS-IN-1
  • HY-13276
    IRAK inhibitor 2 928333-30-6 99.19%
    IRAK inhibitor 2 is an interleukin-1 receptor-associated kinase (IRAK) inhibitor. IRAK inhibitor 2 can be used for the research of inflammatory and immune diseases.
    IRAK inhibitor 2
  • HY-13499
    JNJ-41443532 1228650-83-6 99.65%
    JNJ-41443532 (CCR2 antagonist 5) is a selective, orally active hCCR2 inhibitor with good binding affinity (IC50=37 nM) and potent functional antagonism (chemotaxis IC50=30 nM). JNJ-41443532 displays a Ki of 9.6 µM for mCCR2 binding. JNJ-41443532 can be used in the research of inflammatory disease.
    JNJ-41443532
  • HY-14190
    Valategrast 220847-86-9
    Valategrast (R-411 free base) is a potent and orally active integrin α4β1 (VLA-4) and α4β7 dual antagonist. Valategrast has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment.
    Valategrast
  • HY-14801
    Sivifene 2675-35-6 99.66%
    Sivifene (A-007) is a triaryl hydrazone. Sivifene has anticancer activity and immunomodulatory effects. Sivifene regulates immune regulation by upregulating CD45 T lymphocyte surface receptors.
    Sivifene
  • HY-15280
    GSK2292767 1254036-66-2 98.89%
    GSK2292767 is a potent and selective inhibitor of PI3Kδ, with a pIC50 of 10.1. GSK2292767 showing greater than 500-fold selective over the other PI3K isoforms. GSK2292767 can be used for the research of respiratory disease.
    GSK2292767
  • HY-15652
    Freselestat 208848-19-5 99.68%
    Freselestat (ONO-6818) is a potent and orally active neutrophil elastase inhibitor with a Ki of 12.2 nM. Freselestat is >100-fold less-active against other proteases such as trypsin, protein-ase 3, pancreatic elastase, plasmin, thrombin, collagenase, cathepsin G, and murine macrophage elastase. Freselestat has a potent anti-inflammatory activity.
    Freselestat
  • HY-15891
    GW311616 198062-54-3 99.30%
    GW-311616 is a potent, orally bioavailable, long duration and selective human neutrophil elastase (HNE) inhibitor with IC50 value of 22 nM and Ki value of 0.31 nM.
    GW311616
  • HY-16496
    Thiarabine 26599-17-7 99.66%
    Thiarabine (OSI-7836) shows potent anti-tumor activity and inhibition of DNA synthesis.
    Thiarabine
  • HY-17482
    Difenpiramide 51484-40-3 99.13%
    Difenpiramide (Z-876) is a bisphenylalcanoic derivative with marked anti-inflammatory, analgesic, antipyretic and uricosuric properties. Difenpiramide has platelet anti-aggregation activity.
    Difenpiramide
  • HY-18773
    Oct3/4-inducer-1 1016535-83-3 98.12%
    Oct3/4-inducer-1 (compound 2) is a potent Oct3/4 inducer. Oct3/4-inducer-1 promotes expression and stabilization of Oct3/4, and enhances its transcriptional activity in diverse human somatic cells.
    Oct3/4-inducer-1
  • HY-18956
    (E/Z)-Icerguastat 13098-73-2 99.44%
    (E/Z)-Icerguastat ((E/Z)-Sephin1) is a selective inhibitor of the phosphatase regulatory subunit PPP1R15A (R15A). (E/Z)-Icerguastat can be used for protein misfolding diseases research.
    (E/Z)-Icerguastat
  • HY-19384
    Enflicoxib 251442-94-1 99.88%
    Enflicoxib (E 6087) is a nonsteroidal anti-inflammatory compound that selectively inhibits cyclooxygenase-2 (COX-2).?Enflicoxib does not inhibit cyclooxygenase-1 (COX-1). E-6087 shows anti-inflammatory, analgesic and antipyretic activities in animal models.
    Enflicoxib
  • HY-19655
    Cethromycin 205110-48-1
    Cethromycin (ABT-773) is a ketolide antibiotic.
    Cethromycin
  • HY-19760
    I-BET282 1422554-34-4 98.90%
    I-BET282 is a pan-inhibitor of all eight BET bromodomains, and selectivity over other representative bromodomain-containing proteins. I-BET282 shows pIC50s ranging 6.4-7.7 for BRD2 (BD1/BD2), BRD2 (BD1/BD), BRD3 (BD1/BD), and BRD4 (BD1/BD).
    I-BET282
  • HY-23127
    Decyltriphenylphosphonium bromide 32339-43-8 98.20%
    Decyltriphenylphosphonium bromide is a mitochondrial antioxidant with oral activity. Decyltriphenylphosphonium bromide can be used in the research of autoimmune arthritis.
    Decyltriphenylphosphonium bromide
  • HY-24504
    MBA-m1 305866-70-0 98.20%
    MBA-m1 is a MLKL inhibitor. MBA-m1 inhibits necroptosis in Mlkl−/− NIH-3T3 cells. MBA-m1 ameliorates disease in MLKL-induced dermatitis and abdominal aortic aneurysm mouse model.
    MBA-m1
Cat. No. Product Name / Synonyms Application Reactivity